Mothaffar F. Rimawi, MD

Articles

Dr. Rimawi on Mitigating Interstitial Lung Disease in HER2+ Breast Cancer

October 4th 2021

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

Dr. Rimawi Discusses KATHERINE Trial in HER2+ Breast Cancer

January 19th 2019

Mothaffar F. Rimawi, MD, an associate professor and director of Clinical Research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the KATHERINE trial in HER2-positive breast cancer.

Dr. Rimawi Discusses Role of TKIs in HER2+ Breast Cancer

January 3rd 2019

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the role of TKIs in the treatment of HER2-positive breast cancer.

Dr. Rimawi on Treatment of Metastatic HER2+ Breast Cancer

December 13th 2018

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the current treatment paradigm for patients with metastatic HER2-positive breast cancer.

Dr. Rimawi Discusses Patient Selection in HER2+ Breast Cancer

December 19th 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses patient selection in the treatment of HER2-positive breast cancer.

Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer

December 7th 2017

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.

Dr. Rimawi on Neoadjuvant Estrogen Deprivation Therapy in HER2+ Breast Cancer

December 15th 2016

Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.